Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NovoTTF-200A + Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
NCT03232424Phase 1Completed
- Sponsor
- Hackensack Meridian Health
- Start
- Jul 2017
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Hackensack Meridian Health. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 months. Started Jul 2017; status: completed.
Beyond the preview
Go deeper on NCT03232424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232424.